The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients
Status:
Unknown status
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
This study uses to suppress the growth of tumors, extend the patient's survival time and
improve the quality of life as much as possible. Through the treatment, the patient is given
the chance to undergo surgical resection, thereby more effectively prolonging the OS.
Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant
tumors by inhibiting VEGFR and exerting anti-angiogenic effects. Preclinical studies have
shown that its antitumor effect is better than that of the similar drug PTK787. Phase II
studies of hepatocellular carcinoma have initially demonstrated the effectiveness and safety
of apatinib in the treatment of advanced HCC. TACE embolized tumor artery blood supply to
inhibit tumor growth and shrink tumors. Based on the therapeutic potential of apatinib, and
TACE in their respective tumors, we designed a prospective exploratory clinical study of this
patient with advanced liver cancer.